SCHEMBL4852935

SCHEMBL4852935

O=C(NCc1ccc(Cl)cc1)c1cc(Cl)n[nH]c1=O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 1/20 0.62
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ LMNA P02545 2/20 0.51
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ ADORA2A P29274 2/20 0.47
▸ ADORA1 P30542 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ POLA1 P09884 2/20 0.47
▸ EGLN1 Q9GZT9 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854012 0.82 GSK3B (0.76) GSK3BMEN1KMT2ALMNAMAPT
SCHEMBL4856682 0.82 GSK3B (0.69) GSK3BMEN1KMT2ALMNACYP1A2
SCHEMBL4848658 0.81 GSK3B (0.68) GSK3BMEN1KMT2ALMNACYP1A2
SCHEMBL4854512 0.81 GSK3B (0.71) GSK3BMEN1KMT2ALMNACYP1A2
SCHEMBL4848893 0.80 GSK3B (0.86) GSK3BMEN1KMT2ALMNAADORA2A
SCHEMBL4855933 0.80 GSK3B (0.70) GSK3BMEN1KMT2ALMNAADORA2A
SCHEMBL4856002 0.80 GSK3B (0.70) GSK3BMEN1KMT2AMAPTALDH1A1
SCHEMBL4856883 0.79 GSK3B (0.71) GSK3BMEN1KMT2AL3MBTL1TDP1
SCHEMBL4857443 0.79 GSK3B (0.66) GSK3BMEN1KMT2ALMNACYP1A2
SCHEMBL4856582 0.79 GSK3B (0.66) GSK3BMEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462613-B2 Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-12-09 — — US disclosed
US-7309701-B2 Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-12-18 — — US disclosed
EP-1611121-B1 PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS AVENTIS PHARMA SA (FR) 2007-08-08 — — EP disclosed
EP-1581505-B1 PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-08-01 — — EP disclosed
EP-1581505-A1 PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2005-10-05 — — EP disclosed
US-20050026918-A1 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-02-03 — — US disclosed
US-20040176377-A1 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-09-09 — — US disclosed
WO-2004046117-A1 PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176377-A1 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them ADRA2C, ADRA1A, ADRA1B GSK3B 3654/4885MEN1 1850/4885KMT2A 3158/4885
US-20050026918-A1 Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them C5, ADRA2C, ADRA1A GSK3B 3708/4885MEN1 997/4885KMT2A 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback